Lv41
640 积分 2025-07-28 加入
TYK2 as a novel therapeutic target in psoriasis
1小时前
已完结
Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study
4天前
已完结
Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review
5天前
已完结
TYK2: an emerging therapeutic target in rheumatic disease
5天前
已完结
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis
5天前
已完结
Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System
5天前
已完结
Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database
5天前
已完结
Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database
6天前
已完结
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials
6天前
已关闭
Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study
6天前
已完结
皖公网安备34019202002308
